Evidence map›Paper›PMID 31231471›Full record

ArticleOncotarget2019

Functional characterization of

Richard Glenn C Delacruz, Imelda T Sandoval, Kyle Chang, Braden N Miller, Laura Reyes-Uribe, Ester Borras, Patrick M Lynch, Melissa W Taggart, Ernest T Hawk, Eduardo Vilar and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Zebrafish Cancer Predisposition Models.Frontiers in cell and developmental biology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Richard Glenn C DelacruzFunctional and Chemical Genomics, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
Imelda T SandovalFunctional and Chemical Genomics, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
Kyle ChangDepartment of Clinical Cancer Prevention, The University of Texas UTHealth MD Anderson Cancer Center, Houston, TX, USA.
Braden N MillerFunctional and Chemical Genomics, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
Laura Reyes-UribeDepartment of Clinical Cancer Prevention, The University of Texas UTHealth MD Anderson Cancer Center, Houston, TX, USA.
Ester BorrasDepartment of Clinical Cancer Prevention, The University of Texas UTHealth MD Anderson Cancer Center, Houston, TX, USA.
Patrick M LynchDepartment of Gastroenterology, Hepatology and Nutrition, The University of Texas UTHealth MD Anderson Cancer Center, Houston, TX, USA.
Melissa W TaggartDepartment of Pathology, The University of Texas UTHealth MD Anderson Cancer Center, Houston, TX, USA.
Ernest T HawkDepartment of Clinical Cancer Prevention, The University of Texas UTHealth MD Anderson Cancer Center, Houston, TX, USA.
Eduardo Vilar *Department of Clinical Cancer Prevention, The University of Texas UTHealth MD Anderson Cancer Center, Houston, TX, USA.
David A Jones *Functional and Chemical Genomics, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
The University of Texas MD Anderson Cancer Center · USOklahoma Medical Research Foundation · USThe University of Texas Health Science Center at Houston · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
R25 SUPPLEMENT IN GENETIC EPIDEMIOLOGY EDUCATIONR25CA057730 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHANG, SHINE · 1992 to 2016
$18.6M
APC and Retinoids in Zebrafish Enterocyte DevelopmentR01CA116468 · NCI · UNIVERSITY OF UTAH · PI JONES, DAVID A · 2005 to 2020
$4.2M
Discovering New Targets for Chemoprevention in Familial Adenomatous PolyposisR03CA176788 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI VILAR SANCHEZ, EDUARDO · 2014 to 2015
$160k
NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA116468NCI NIH HHS R03 CA176788NCI NIH HHS R25 CA057730
6 · The paper itself

Abstract

Germline mutations in the tumor suppressor

Indexed as

APCCNOT3colon cancerCtBP1familial adenomatous polyposis

Identifiers

PMID31231471
PMCPMC6570471
OpenAlexW2969632721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.